Presentation is loading. Please wait.

Presentation is loading. Please wait.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin.

Similar presentations


Presentation on theme: "Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin."— Presentation transcript:

1 Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse  John W. Sweetenham, MD, FRCP, Jan Walewski, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD, PhD, Edward Agura, MD, Jerzy Holowiecki, MD, PhD, Muneer H. Abidi, MD, Andy I. Chen, MD, PhD, Pat Stiff, MD, Simonetta Viviani, Angelo Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, PhD, Anna Sureda, MD, PhD, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N. Hunder, MD, Craig H. Moskowitz, MD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S36-S37 (March 2016) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 PFS per Investigator.
Biology of Blood and Marrow Transplantation  , S36-S37DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin."

Similar presentations


Ads by Google